Nelfinavir therapy observed no serious adverse events in COVID-19 patients
abnormal sitting diastolic blood pressure
ADVERSE EVENTS
The adverse events occurred during the trial were all grade 1. Among them, 10 patients in the nelfinavir group (After treatment, there were no clinically significant patients with abnormal sitting diastolic blood pressure, sitting systolic blood pressure, respiratory rate, and pulse in the two groups.